术前调强放疗联合同期卡培他滨化疗的新辅助放化疗在进展期胃癌的应用(1)
[摘要] 目的 观察术前调强放疗联合同期卡培他滨化疗的新辅助放化疗在进展期胃癌的应用效果。方法 选取该院84例进展期胃癌患者，采用随机数字表法分组，各42例。对照组予以术前卡培他滨联合奥沙利铂的新辅助化疗，观察组予以术前卡培他滨联合调强放疗的新辅助放化疗。对比两组客观缓解率(ORR)、不良反应发生情况、生存情况。 结果 观察组ORR 66.67%(28/42)较对照组45.24%(19/42)高(P<0.05);观察组不良反应发生率11.90%(5/42)与对照组7.14%(3/42)对比差异无统计学意义(P>0.05);观察组1年生存率80.95%(34/42)较对照组59.52%(25/42)高，2年生存率73.81%(31/42)较对照组52.38%(22/42)高，局部复发率4.76%(2/42)较对照组23.81%(10/42)低，远处转移率9.52%(4/42)较对照组28.57%(12/42)低(P<0.05)。 结论 术前调强放疗联合同期卡培他滨化疗的新辅助放化疗治疗进展期胃癌，可提高治疗效果，改善患者生存率，减少局部复发、远处转移，安全性高。
[关键词] 进展期胃癌;术前;调强放疗;卡培他滨;新辅助放化疗
[中图分类号] R735.2 [文献标识码] A [文章编号] 1674-0742(2019)04(a)-0118-03
[Abstract] Objective To observe the effect of preoperative intensity-modulated radiotherapy combined with neoadjuvant chemotherapy with capecitabine in advanced gastric cancer. Methods Convenient select eighty-four patients with advanced gastric cancer were enrolled in our hospital. They were randomly divided into two groups， with 42 cases in each group. The control group received neoadjuvant chemotherapy with capecitabine plus oxaliplatin before surgery. The observation group received neoadjuvant chemoradiation with preoperative capecitabine combined with intensity-modulated radiotherapy. Results The ORR of the observation group was 66.67% (28/42) higher than that of the control group was 45.24% (19/42) (P<0.05). The incidence of adverse reactions in the observation group was 11.90% (5/42) and the control group was 7.14% (3/42). There the difference was statistically significant(P>0.05). The 1-year survival rate of the observation group was 80.95% (34/42) higher than that of the control group was 59.52% (25/42)， and the 2-year survival rate was 73.81% (31/42) compared with the control group. 52.38% (22/42) high， local recurrence rate was 4.76% (2/42) lower than 23.81% (10/42) in the control group， and distant metastasis rate was 9.52% (4/42) compared with 28.57%(12/42) in the control group (P< 0.05). Conclusion Preoperative intensity-modulated radiotherapy combined with neoadjuvant radiotherapy combined with capecitabine chemotherapy for advanced gastric cancer can improve the treatment effect， improve patient survival rate， reduce local recurrence， distant metastasis， and have high safety.
[Key words] Advanced gastric cancer; Preoperative; Intensity-modulated radiotherapy; Capecitabine; Neoadjuvant chemoradiation
胃癌為常见恶性肿瘤，全球每年约有65万人死于胃癌[1]。进展期胃癌指癌组织突破黏膜下层，侵入胃壁肌层、浆膜层。新辅助化疗是进展期胃癌术前治疗的重要方式，可杀灭转移细胞，缩小肿块。近年来，调强放疗在癌症治疗中的作用突显，受到广泛关注。调强放疗可按靶区三维形状等解剖关系调节射线束强度，在杀伤癌细胞的同时，减小对周围组织损伤。该研究以该院2011年2月—2017年11月84例进展期胃癌患者为对象，予以术前调强放疗联合同期卡培他滨化疗的新辅助放化疗，观察对进展期胃癌患者的影响，报道如下。, 百拇医药(蒋莹 金珊 沈齐)
[关键词] 进展期胃癌;术前;调强放疗;卡培他滨;新辅助放化疗
[中图分类号] R735.2 [文献标识码] A [文章编号] 1674-0742(2019)04(a)-0118-03
[Abstract] Objective To observe the effect of preoperative intensity-modulated radiotherapy combined with neoadjuvant chemotherapy with capecitabine in advanced gastric cancer. Methods Convenient select eighty-four patients with advanced gastric cancer were enrolled in our hospital. They were randomly divided into two groups， with 42 cases in each group. The control group received neoadjuvant chemotherapy with capecitabine plus oxaliplatin before surgery. The observation group received neoadjuvant chemoradiation with preoperative capecitabine combined with intensity-modulated radiotherapy. Results The ORR of the observation group was 66.67% (28/42) higher than that of the control group was 45.24% (19/42) (P<0.05). The incidence of adverse reactions in the observation group was 11.90% (5/42) and the control group was 7.14% (3/42). There the difference was statistically significant(P>0.05). The 1-year survival rate of the observation group was 80.95% (34/42) higher than that of the control group was 59.52% (25/42)， and the 2-year survival rate was 73.81% (31/42) compared with the control group. 52.38% (22/42) high， local recurrence rate was 4.76% (2/42) lower than 23.81% (10/42) in the control group， and distant metastasis rate was 9.52% (4/42) compared with 28.57%(12/42) in the control group (P< 0.05). Conclusion Preoperative intensity-modulated radiotherapy combined with neoadjuvant radiotherapy combined with capecitabine chemotherapy for advanced gastric cancer can improve the treatment effect， improve patient survival rate， reduce local recurrence， distant metastasis， and have high safety.
[Key words] Advanced gastric cancer; Preoperative; Intensity-modulated radiotherapy; Capecitabine; Neoadjuvant chemoradiation
胃癌為常见恶性肿瘤，全球每年约有65万人死于胃癌[1]。进展期胃癌指癌组织突破黏膜下层，侵入胃壁肌层、浆膜层。新辅助化疗是进展期胃癌术前治疗的重要方式，可杀灭转移细胞，缩小肿块。近年来，调强放疗在癌症治疗中的作用突显，受到广泛关注。调强放疗可按靶区三维形状等解剖关系调节射线束强度，在杀伤癌细胞的同时，减小对周围组织损伤。该研究以该院2011年2月—2017年11月84例进展期胃癌患者为对象，予以术前调强放疗联合同期卡培他滨化疗的新辅助放化疗，观察对进展期胃癌患者的影响，报道如下。, 百拇医药(蒋莹 金珊 沈齐)